Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis.

Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ.

Chest. 2014 Nov;146(5):1256-1262. doi: 10.1378/chest.14-0492.

2.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

3.

Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study.

Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, Nathan SD.

Chest. 2015 Jan;147(1):173-179. doi: 10.1378/chest.13-2424.

PMID:
25188694
4.

Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.

Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA.

JAMA. 2013 Jun 5;309(21):2232-9. doi: 10.1001/jama.2013.5827.

5.

Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.

Yu YF, Wu N, Chuang CC, Wang R, Pan X, Benjamin NN, Devercelli G, Coultas DB.

J Manag Care Spec Pharm. 2016 Apr;22(4):414-23. doi: 10.18553/jmcp.2016.22.4.414.

6.

Composite end points of death and hospitalization are the only appropriate option for most trials.

Latar I, Girerd N.

Chest. 2015 May;147(5):e189. doi: 10.1378/chest.14-3246. No abstract available.

PMID:
25940263
7.

Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis.

Kim ES, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM.

Chest. 2015 Feb;147(2):430-437. doi: 10.1378/chest.14-0453.

PMID:
25211374
8.

End-of-life care of patients with idiopathic pulmonary fibrosis.

Rajala K, Lehto JT, Saarinen M, Sutinen E, Saarto T, Myllärniemi M.

BMC Palliat Care. 2016 Oct 12;15(1):85.

9.

A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival.

Kulkarni T, Willoughby J, Acosta Lara Mdel P, Kim YI, Ramachandran R, Alexander CB, Luckhardt T, Thannickal VJ, de Andrade JA.

Respir Med. 2016 Jun;115:33-8. doi: 10.1016/j.rmed.2016.04.010. Epub 2016 Apr 20.

10.
11.

Clinical and functional outcomes in Middle Eastern patients with idiopathic pulmonary fibrosis.

Alhamad EH, Masood M, Shaik SA, Arafah M.

Clin Respir J. 2008 Oct;2(4):220-6. doi: 10.1111/j.1752-699X.2008.00070.x.

PMID:
20298338
12.

[A retrospective cohort study of prognostic factors for death in patients with idiopathic pulmonary fibrosis].

Li ZH, Peng SC, Kang J, Hou XM, Yu RJ.

Zhonghua Jie He He Hu Xi Za Zhi. 2010 Dec;33(12):887-91. Chinese.

PMID:
21211406
13.

Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.

Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ; IPFnet investigators.

Lancet Respir Med. 2015 May;3(5):388-96. doi: 10.1016/S2213-2600(15)00093-4. Epub 2015 Apr 15.

14.

Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.

Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G.

Ann Am Thorac Soc. 2015 Jul;12(7):981-7. doi: 10.1513/AnnalsATS.201412-553OC.

PMID:
25923447
15.

Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival.

Lee T, Park JY, Lee HY, Cho YJ, Yoon HI, Lee JH, Jheon S, Lee CT, Park JS.

Respir Med. 2014 Oct;108(10):1549-55. doi: 10.1016/j.rmed.2014.07.020. Epub 2014 Aug 15.

16.

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).

Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95. doi: 10.1164/rccm.201202-0314OC. Epub 2012 May 3.

17.

Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.

Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD.

Respir Med. 2015 Dec;109(12):1582-8. doi: 10.1016/j.rmed.2015.11.001. Epub 2015 Nov 6.

18.

Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis.

Rangappa P, Moran JL.

Crit Care Resusc. 2009 Jun;11(2):102-9.

PMID:
19485873
19.

The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010.

Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB.

Chest. 2013 Apr;143(4):1078-1084. doi: 10.1378/chest.12-0803.

PMID:
23188187
20.

Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, Xue J, Zhang Y, Duncan SR.

PLoS One. 2015 Jun 17;10(6):e0127771. doi: 10.1371/journal.pone.0127771. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0133684.

Supplemental Content

Support Center